SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Parabilis Medicines (PBLS) Reports $44.5M Q3 Loss; Cash Runway Expected Into 2030

Parabilis reported a Q3 2026 net loss of $44.5M versus $33.5M a year earlier and revenue of $2.1M versus none. Cash, equivalents and marketable securities were $1.1B at September 30, 2026, expected to fund operations into 2030.Material DetailsContext by AI AnalystThe results reflect a clinical-stag…

PBLS

Related stories